

A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects

NCT05913752

| | |
|------------|-------------------------|
| Status | RECRUITING |
| Phase | Phase 1, Phase 2 |
| Sponsor | Clearmind Medicine Inc. |
| Enrollment | 84 participants |

Key Eligibility Criteria

Inclusion (15)

- All Subjects
 - Signed informed consent prior to any study-related procedures,
 - Subjects understand the nature and the procedures related with the study design of the trial and accept to fulfill all activities related to this trial,
 - Subjects 18 to 60 years of age,
 - Body mass index between 18 and 35 kg/m², with a weight above 60 kg.
- ... and 10 more (see full listing online)

Exclusion (16)

- The subject has a clinically significant history of a disease or a disorder that could interfere with the interpretation of the results or could increase the risk to the subject all according to the opinion of the PI,
 - Subject has a substance use disorder at time of screening (except for alcohol use in AUD subjects and nicotine use disorders),
 - Subjects with cannabis or other drug use for at least 5 half-lives prior to screening, including nicotine use (i.e., subjects must abstain from nicotine use for at least five half-lives prior to screening).
 - Subjects with symptoms of alcohol withdrawal or intoxication at time of screening (assessed using CIWA-Ar tool). if medically appropriate, intoxicated individuals will be provided transportation home while those experiencing alcohol withdrawal will be referred to an appropriate level of care.
 - Subjects with history of seizures or epilepsy,
- ... and 11 more (see full listing online)

Locations (4 total)

Connecticut Mental Health Center, New Haven, Connecticut, United States
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
Hadassah Medical Center, Jerusalem, Israel
... and 1 more locations